Double maintains 3 strategies that include EXEL - Exelixis, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KRNT | 39.72% | $880.26M | +27.76% | 0.00% |
CIM | 35.04% | $1.15B | +6.95% | 10.45% |
FSP | 34.86% | $173.99M | +12.00% | 2.38% |
JAZZ | 34.39% | $6.60B | +8.51% | 0.00% |
GRMN | 32.94% | $41.09B | +32.15% | 1.47% |
DT | 32.02% | $16.86B | +30.29% | 0.00% |
CAKE | 31.56% | $3.13B | +68.59% | 1.70% |
PRAA | 31.31% | $627.00M | -17.14% | 0.00% |
V | 31.20% | $687.53B | +33.57% | 0.64% |
ADP | 30.98% | $124.58B | +30.76% | 1.96% |
RYAM | 30.96% | $276.45M | -23.76% | 0.00% |
BBU | 30.31% | $2.32B | +36.01% | 0.97% |
MA | 30.13% | $510.72B | +26.48% | 0.50% |
PAYO | 29.83% | $2.44B | +22.06% | 0.00% |
OMCL | 29.68% | $1.39B | +14.43% | 0.00% |
BRSP | 29.56% | $656.22M | -16.58% | 12.72% |
FTNT | 29.42% | $82.31B | +78.40% | 0.00% |
PRI | 29.29% | $8.96B | +16.88% | 1.41% |
CWEN.A | 28.73% | $3.51B | +32.62% | 5.67% |
D | 28.46% | $48.03B | +13.82% | 4.73% |
Current Value
$43.531 Year Return
Current Value
$43.531 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
QRVO | 0.01% | $8.17B | -26.45% | 0.00% |
NEM | 0.04% | $64.12B | +31.26% | 1.73% |
WBTN | 0.06% | $1.23B | -53.54% | 0.00% |
MSIF | 0.07% | $777.96M | +37.67% | 7.52% |
HUM | 0.08% | $28.66B | -36.39% | 1.50% |
NIO | -0.08% | $6.80B | -22.22% | 0.00% |
FUTU | -0.11% | $14.72B | +97.62% | 0.00% |
BTG | -0.12% | $4.65B | +26.16% | 3.42% |
CYRX | 0.13% | $381.04M | +26.67% | 0.00% |
HY | 0.13% | $745.22M | -35.62% | 3.32% |
CRVO | 0.15% | $54.87M | -58.71% | 0.00% |
PINC | -0.15% | $1.80B | +18.55% | 3.82% |
GTN | 0.16% | $531.36M | +14.47% | 6.08% |
ANIP | -0.19% | $1.41B | +6.08% | 0.00% |
TEF | -0.21% | $29.46B | +22.82% | 6.25% |
DAO | 0.26% | $274.96M | +140.82% | 0.00% |
IRWD | -0.26% | $122.14M | -88.06% | 0.00% |
JBI | 0.27% | $1.25B | -27.15% | 0.00% |
VSA | 0.27% | $8.76M | -15.57% | 0.00% |
RDUS | 0.28% | $847.17M | +104.64% | 2.50% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
MLN | -0.06% | $514.61M | 0.24% |
LMBS | 0.09% | $5.10B | 0.64% |
COMT | -0.09% | $614.10M | 0.48% |
HYD | -0.11% | $3.31B | 0.32% |
IBTH | -0.16% | $1.61B | 0.07% |
CMF | 0.19% | $3.58B | 0.08% |
MMIN | -0.20% | $327.85M | 0.3% |
IBMS | 0.24% | $89.52M | 0.18% |
TFI | 0.27% | $3.22B | 0.23% |
SCHO | 0.28% | $11.00B | 0.03% |
DBC | 0.30% | $1.26B | 0.87% |
BILZ | 0.39% | $861.77M | 0.14% |
COM | 0.39% | $209.85M | 0.72% |
SIVR | 0.40% | $2.03B | 0.3% |
BSMR | -0.40% | $258.34M | 0.18% |
IAGG | 0.55% | $10.48B | 0.07% |
UCON | 0.74% | $2.96B | 0.86% |
BSV | 0.84% | $37.94B | 0.03% |
GSG | 0.84% | $1.01B | 0.75% |
IGOV | -0.88% | $1.23B | 0.35% |
SeekingAlpha
Upgrade alert: Exelixis (EXEL) moves to 'Buy' with a de-risked pipeline, strong financials, and breakthrough phase 3 results. See more analysis here.
Yahoo
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
Yahoo
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
Yahoo
Pfizer is slowly building a foundation that will help its business recover from recent headwinds. Encouraging developments on the clinical front should boost shares of cancer specialist Exelixis. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.
Yahoo
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Yahoo
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FBT | 33.11% | $1.02B | 0.54% |
PBE | 32.99% | $228.63M | 0.58% |
SMMV | 30.57% | $323.27M | 0.2% |
DVY | 30.15% | $20.25B | 0.38% |
CDC | 29.08% | $750.81M | 0.42% |
XMLV | 29.08% | $823.12M | 0.25% |
FTCS | 28.96% | $8.51B | 0.52% |
LGLV | 28.83% | $1.10B | 0.12% |
FDLO | 28.60% | $1.24B | 0.16% |
OUSA | 28.50% | $824.59M | 0.48% |
MDIV | 28.50% | $452.75M | 0.75% |
IXG | 28.47% | $532.75M | 0.41% |
XLF | 28.46% | $51.31B | 0.09% |
XPH | 28.25% | $150.90M | 0.35% |
SPLV | 28.13% | $7.71B | 0.25% |
VFH | 28.09% | $12.75B | 0.09% |
FVD | 28.00% | $9.12B | 0.61% |
IYG | 27.94% | $1.85B | 0.39% |
DLN | 27.85% | $5.11B | 0.28% |
FNCL | 27.66% | $2.31B | 0.084% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -20.31% | $95.09M | 0.59% |
VIXY | -18.63% | $185.99M | 0.85% |
BTAL | -12.21% | $312.42M | 1.43% |
IVOL | -12.09% | $342.02M | 1.02% |
CTA | -10.61% | $1.06B | 0.76% |
TBLL | -8.65% | $2.12B | 0.08% |
SHYD | -8.26% | $331.76M | 0.35% |
FXE | -7.84% | $585.58M | 0.4% |
GBIL | -7.05% | $6.35B | 0.12% |
BILS | -6.97% | $3.80B | 0.1356% |
BAR | -6.45% | $1.12B | 0.1749% |
IAU | -6.33% | $47.38B | 0.25% |
SGOL | -6.33% | $5.24B | 0.17% |
OUNZ | -6.27% | $1.74B | 0.25% |
GLD | -6.19% | $101.49B | 0.4% |
AAAU | -6.13% | $1.57B | 0.18% |
SHYM | -6.01% | $355.63M | 0.35% |
PPLT | -5.99% | $1.68B | 0.6% |
GLDM | -5.70% | $15.92B | 0.1% |
SIL | -5.10% | $2.04B | 0.65% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DAVA | -15.79% | $674.11M | -48.05% | 0.00% |
AIFU | -15.42% | $15.34M | +65.63% | 0.00% |
TXO | -11.64% | $825.60M | -26.56% | 15.78% |
LEGN | -11.23% | $6.90B | -19.74% | 0.00% |
BGFV | -9.92% | $32.35M | -43.37% | 0.00% |
SGC | -9.77% | $175.97M | -42.27% | 5.04% |
STG | -9.34% | $31.09M | -22.74% | 0.00% |
LITB | -9.14% | $23.17M | -74.54% | 0.00% |
EXK | -8.54% | $1.40B | +21.61% | 0.00% |
AGI | -8.41% | $10.98B | +56.29% | 0.38% |
OPCH | -8.32% | $5.05B | +14.34% | 0.00% |
ATNI | -8.26% | $278.46M | -10.64% | 5.43% |
IMDX | -8.15% | $83.22M | -2.68% | 0.00% |
SMCI | -8.13% | $29.31B | -45.17% | 0.00% |
WST | -8.00% | $15.84B | -30.80% | 0.38% |
GIFI | -7.88% | $113.57M | +13.64% | 0.00% |
HRMY | -7.51% | $1.88B | -5.26% | 0.00% |
ODP | -7.40% | $582.40M | -47.22% | 0.00% |
OR | -7.04% | $4.84B | +62.23% | 0.75% |
MKTX | -6.97% | $8.13B | +6.08% | 1.38% |